Prostate cancer cell lines lack amplification: Overexpression of HER2

Ullén, Anders; Lennartsson, Lena; Harmenberg, Ulrika; Lennernäs, Bo; Majumder, Khairul; Holmberg, Anders; Nilsson, Sten; Elmberger, Göran

doi:10.1080/02841860510029888

Cited by 11 publications

(11 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…K-RAS is not only an oncogene, but also a known target in differentiation therapy of PCA (Benbrahim-Tallaa et al, 2005. ERBB2 overexpression is important in PCA and our finding is in concordance with previous observations (Liu et al, 2001;Calvo et al, 2003;Ullén et al, 2005). Taken together, two well-known genes, FOS and IL1B, were upregulated as members of the same pathway as well.…”

Section: Discussionsupporting

confidence: 82%

Gene network and canonical pathway analysis in prostate cancer: a microarray study

et al. 2008

View full text Add to dashboard Cite

The molecular mechanism playing a role in the development of prostate cancer (PCA) is not well defined. We decided to determine the changes in gene expression in PCA tissues and to compare them to those in noncancerous samples. Prostate tissue samples were collected by needle biopsy from 21 PCA and 10 benign prostate hyperplasic (BPH) patients. Total RNA was isolated, cDNA was synthesized, and gene expression levels were determined by microarray method. In the progression to PCA, 738 up-regulated and 515 downregulated genes were detected in samples. Analysis using Ingenuity Pathway Analysis (IPA) software revealed that 466 network and 423 functions-pathways eligible genes were up-regulated, and 363 network and 342 functions-pathways eligible genes were down-regulated. Up-regulated networks were identified around IL-1β and insulin-like growth factor-1 (IGF-1) genes. The NFKB gene was centered around two upand down-regulated networks. Up-regulated canonical pathways were assigned and four of them were evaluated in detail: acute phase response, hepatic fibrosis, actin cytoskeleton, and coagulation pathways.Axonal guidance signaling was the most significant down-regulated canonical pathway. Our data provide not only networks between the genes for understanding the biologic properties of PCA but also useful pathway maps for future understanding of disease and the construction of new therapeutic targets.

show abstract

Section: Discussionsupporting

confidence: 82%

Gene network and canonical pathway analysis in prostate cancer: a microarray study

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Therefore, it is not unexpected that there is a wide range of reported overexpression of HER2/neu in prostate adenocarcinoma, which extends from no overexpression [348] to 100% [349], averaging 55% for prostate carcinoma, including a recent meta-analysis [347][348][349][350][351][352][353][354][355][356][357][358][359][360]. The general consensus is that a substantial number of advanced prostate adenocarcinomas overexpress HER2/neu [347][348][349][353][354][355][356][357][358][359][360], with little or no gene amplification [358][359][360][361][362][363][364]. Variable expression of HER2/neu has been reported in prostate adenocarcinoma (none to 100%), HER2/neu overexpression is inversely correlated with Gleason Score and metastatic tumor [357][358][359][360][361][362][363][364].…”

Section: Prostatementioning

confidence: 99%

HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology

Nelson¹

2014

Clinical Investigation

View full text Add to dashboard Cite

No biological molecule in the field of oncology has been more extensively or more successfully targeted for therapeutic intent than the product of the c-erbB2 gene, HER2/neu. This is the second of a comprehensive three-part review of the foundation for and therapeutic targeting of HER2/neu. The distribution of HER2/neu overexpression and/or gene amplification by individual tumor sites and histologies will be comprehensively surveyed and described. This provides a bridge between the primarily basic science focused Part I, and the survey of clinical applications to follow in Part III. In combination, this comprehensive survey will identify opportunities and promising areas for future evaluation of HER2/neu-targeted therapies, highlighting the importance of HER2/neu as an increasingly important therapeutic target.

show abstract

“…We chose two tumor models with different HER2 expression levels as examples: SKOV3 human ovarian cancer (high HER2 expression) [11] and PC-3 human prostate carcinoma (low HER2 expression) [41]. We did the intravenous injection (200 μL per mouse) into the athymic nude mice bearing subcutaneous tumors and used IVIS 200 instrument to take the fluorescence imaging studies at multiple time points (0.5, 1, 4, 6, and 24 h).…”

Section: Resultsmentioning

confidence: 99%

Affibody-based nanoprobes for HER2-expressing cell and tumor imaging

et al. 2011

View full text Add to dashboard Cite

This article reports the affibody-based nanoprobes specifically target and image human epidermal growth factor receptor type 2 (HER2)-expressing cells and tumors. The simple, robust, and precise structure of affibody molecules are a promising class of targeting ligands with high affinity. Using near-infrared (NIR) quantum dots (QDs) and iron oxide (IO) nanoparticles as two representative nanomaterials, we designed anti-HER2 affibody molecules with an N-terminus cysteine residue (Cysteine-Z HER2:342 ) and precisely conjugated with maleimide-functionalized nanoparticles to make nanoparticle-affibody conjugates. The in vitro and in vivo study showed the conjugates are highly specific to target and image HER2-expressing cells and tumors. This work indicated the nanoparticle-affibody conjugates may be excellent candidates as targeting probes for molecular imaging and diagnosis.

show abstract

Prostate cancer cell lines lack amplification: Overexpression of HER2

Cited by 11 publications

References 17 publications

Gene network and canonical pathway analysis in prostate cancer: a microarray study

Gene network and canonical pathway analysis in prostate cancer: a microarray study

HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology

Affibody-based nanoprobes for HER2-expressing cell and tumor imaging

Contact Info

Product

Resources

About